Recent Posts
Social•Feb 19, 2026
Galleri Test Misses Primary Goal, Shows Secondary Promise
A key study of $GRAL's Galleri test in the UK failed to reach its primary endpoint, but showed benefits on a secondary endpoint. Tell me what you all think. https://t.co/CDrvokqPop
By Matthew Herper
Social•Feb 19, 2026
Former Psilocybin Trial Participant Shocked by New Findings
"I took part in a 2012 psilocybin trial. What I’m seeing now horrifies me" https://t.co/T1BLv6n59X via @statnews
By Matthew Herper
Social•Feb 18, 2026
FDA Chief: Most Drugs Belong Over‑the‑counter
FDA chief Marty Makary says 'everything should be over the counter' unless drug is unsafe or addictive https://t.co/HiYBuxvyWC
By Matthew Herper
Social•Feb 18, 2026
Federal Vaccine Panel Meeting Delayed After HHS Missed Deadlines
Upcoming meeting of federal vaccine panel may be postponed after HHS missed deadlines https://t.co/zfAl7owoQg via @statnews
By Matthew Herper
Social•Feb 18, 2026
FDA Splits Moderna Flu Vaccine Review by Age
FDA agrees to review Moderna flu vaccine application, splitting review into standard approval for those under 65 and accelerated approval for those 65 and above. $mrna https://t.co/HMMlPm0PGh
By Matthew Herper
Social•Feb 13, 2026
FDA Rejects Review of Moderna’s Experimental Flu Vaccine Data
Here the Moderna flu data the FDA refused to review. This is the most important slide from the company's study of its experimental flu vaccine-- exactly the data FDA said it wouldn't even review. And below is a thread of...
By Matthew Herper
Social•Jan 30, 2026
Regeneron Unveils Next‑Gen Dupixent Amid Rising Competition
There's a fascinating fight brewing between Regeneron and, well, everybody else. But what do we call it? Dupixent, the treatment for atopic dermatitis and other autoimmine issues that $REGN sells with Sanofi, is one of the biggest selling drugs in the...
By Matthew Herper
Social•Jan 30, 2026
Moderna Swaps Vaccine Chief as Development Hurdles Rise
Another possible data point on the challenges for new vaccine development: Moderna's chief medical officer, Jacqueline Miller, a longtime vaccine developer who rose through the ranks at GSK and Merck, is departing. David Berman, a veteran of immuno-oncology efforts at AstraZeneca...
By Matthew Herper
Social•Jan 29, 2026
FDA Rejects Anktiva Expansion After Mischaracterized Meeting
My colleague @adamfeuerstein is reporting today that @DrPatrick "mischaracterized the outcome of a face-to-face meeting he had with FDA officials" to broaden the use of Anktiva, the bladder cancer drug that is sold by ImmunityBio, where Soon-Shiong is chairman. Adam reports...
By Matthew Herper
Social•Jan 29, 2026
Ex‑Vaccine Court Lawyer Now Guides
This Teen Never Got His Day in Vaccine Court. His Former Lawyer Now Advises RFK on Its Overhaul. This story complicates the simple. https://t.co/RSrad8WOnh
By Matthew Herper
Social•Jan 26, 2026
Hospital Group Challenges Eli Lilly's 340B Data Policy
Hospital group seeks to have new Eli Lilly policy on 340B claims data blocked https://t.co/Uz0lDrgL1y
By Matthew Herper
Social•Jan 26, 2026
Shared Vaccine Decision‑making Isn’t the Enemy, Says Sandman
I think you should always listen to Peter Sandman, even if you don't agree. "Shared decision-making on vaccines is not the enemy," one of the great experts on medical decision-making writes in STAT. https://t.co/1XZnI9JZ1m
By Matthew Herper
Social•Jan 26, 2026
Remember William Foege: Smallpox Eradication’s Rational Hero
I don't know how to ask for a moment of silence amid the madness that is X. But please take a moment to reflect on the heroism of William Foege. Foege, who died Saturday at 89, was a key architect of...
By Matthew Herper